ClinicalTrials.gov
public full text
Public Domain
Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease.
This Expanded Access IND is to evaluate the safety of multiple intravenous administrations of HB-adMSCs for treating Parkinson's disease in 10 patients between 76 and 95 y/o who do not qualify for other investigations.The dose to use for this expanded access is 200 million HB-adMSCs, administered through intravenous infusion only, with a treatment duration of 18 weeks. The program includes an up to 28 days screening period, an 18-week Treatment Period, and a 6-week Safety Follow-up Period.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease#981681
- Closed-loop DBS in Parkinson's Disease#1438328
- A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.#918970
- A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease#1060742
- A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients#1138692
Record · ID 1475647
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive